Anemia in elderly people: Risk marker or risk factor?

CMAJ. Canadian Medical Association Journal

Volumn 181, Issue 3-4, 2009, Pages 129-130

  Paltiel, Ora ^a   Clarfield, A Mark ^b,c  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^b BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

^c MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANEMIC AGENT; ERYTHROPOIETIN; HEMOGLOBIN; INTERLEUKIN 6; RECOMBINANT ERYTHROPOIETIN;

AGING; ANEMIA; CLINICAL TRIAL; COGNITIVE DEFECT; COMORBIDITY; DISEASE ASSOCIATION; ERYTHROPOIESIS; HEMOGLOBIN BLOOD LEVEL; HUMAN; IRON DEFICIENCY; MORTALITY; NOTE; NUTRITIONAL DEFICIENCY; PATHOPHYSIOLOGY; PHYSICAL DISABILITY; PREVALENCE; QUALITY OF LIFE; RISK FACTOR;

EID: 68549119143     PISSN: 08203946     EISSN: 14882329     Source Type: Journal    
DOI: 10.1503/cmaj.091199     Document Type: Note

References (12)

1. Guralnik JM, Ershler WB, Schrier SL, et al. Anemia in the elderly: a public health crisis in hematology. Hematology Am Soc Hematol Educ 2005:528-32.
2. den Elzen WPJ, Willems JM, Westendorp RGJ, et al. Effect of anemia and comorbidity on functional status and mortality in old age: results from the Leiden 85-plus Study. CMAJ 2009;DOI:10.1503/cmaj.090040.
3. Eisenstaedt R, Penninx BWJH, Woodman RC. Anemia in the elderly: current understanding and emerging concepts. Blood Rev 2006;20:213-26.
4. Makipour S, Kanapuru B, Ershler WB. Unexplained anemia in the elderly. Semin Hematol 2008;45:250-4.
5. Burch GE. Of senile anemia. Am Heart J 1980;100:407.
6. Lefebvre P, Vekeman F, Sarokhan B, et al. Relationship between hemoglobin level and quality of life in anemic patients with chronic kidney disease receiving epoetin alfa. Curr Med Res Opin 2006;22:1929-37.
7. Patrick DL, Gagnon DD, Zagari MJ, et al.; Epoetin Alfa Study Group. Assessing the clinical significance of health-related quality of life (HrQOL) improvements in anaemic cancer patients receiving epoetin alfa. Eur J Cancer 2003;39:335-45.
8. Tonelli M, Hemmelgarn B, Reiman T. Benefits and harms of erythropoiesis-stimulating agents for anemia related to cancer: a meta-analysis. CMAJ 2009;180:E63-E71.
9. Bohlius J, Schmidlin K, Brillant C, et al. Recombinant human erythropoiesis-stimulating agents and mortality in patientwith cancer: a meta-analysis of randomised trials. Lancet 2009;373:1532-42.
10. Phrommintikul A, Haas SJ, Elsik M, et al. Mortality and target haemoglobin concentrations in anaemic patients with chronic kidney disease treated with erythropoietin: a meta-analysis. Lancet 2007;369:381-8.
11. Zarychanski R, Houston DS. Anemia of chronic disease: A harmful disorder or an adaptive, beneficial response? CMAJ 2008;179:333-7.
12. Agnihotri P, Telfer M, Butt Z, et al. Chronic anemia and fatigue in elderly patients: results of a randomized, double-blind, placebo-controlled, crossover exploratory study with epoetin alfa. J Am Geriatr Soc 2007;55:1557-65.